Bedaquiline kills persistent Mycobacterium tuberculosis with no disease relapse: an in vivo model of a potential cure
- 20 February 2019
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 74 (6) , 1627-1633
Abstract
Objectives: Non-replicating persistent Mycobacterium tuberculosis is difficult to kill since the organisms become undetectable using our conventional diagnostic methods and tolerant to anti-TB drugs. Resuscitation-promoting factors (RPFs) have been used to 'wake up' non-replicating persisters, making them easy to detect. Bedaquiline is a novel bactericidal and sterilizing anti-TB drug with the potential to eradicate RPF-dependent persistent M. tuberculosis. We present the first head-to-head comparison between the standard anti-TB regimen and a bedaquiline-modified regimen in eradicating RPF-dependent persistent M. tuberculosis, using the well-defined Cornell Model. Methods: M. tuberculosis-infected mice were treated for 14 weeks with either the standard regimen (rifampicin, isoniazid, pyrazinamide and ethambutol) or the same regimen where ethambutol was replaced by bedaquiline. The efficacy of both drug regimens was measured by cfu count elimination and eradication of persistent bacteria, which was evaluated using culture filtrate (CF) containing RPFs. At the end of treatment, the remaining cfu count-negative mice were administered hydrocortisone for 8 weeks. The induced disease relapse rates were determined by the percentage of mice that became positive for M. tuberculosis in the lung, spleen or both. Results: The bedaquiline-containing regimen achieved total organ cfu count clearance at 8 weeks after treatment initiation, faster than the standard regimen (14 weeks). Importantly, the bedaquiline-containing regimen removed CF-dependent persistent bacilli at 8 weeks, leading to no disease relapse. Conclusions: A bedaquiline regimen eradicated persistent TB infections and completely prevented disease relapse in mice. These findings offer the potential for a faster cure for TB, with reduced relapse rate.Keywords
Funding Information
- Innovative Medicines Initiative Joint Undertaking
- European Union’s Seventh Framework Programme (FP7/2007–2013)
- EFPIA companies’ in-kind contribution (115337)
- MRC (MR/P011144/1)
This publication has 37 references indexed in Scilit:
- Randomized Dose-Ranging Study of the 14-Day Early Bactericidal Activity of Bedaquiline (TMC207) in Patients with Sputum Microscopy Smear-Positive Pulmonary TuberculosisAntimicrobial Agents and Chemotherapy, 2013
- Short-Course Chemotherapy with TMC207 and Rifapentine in a Murine Model of Latent Tuberculosis InfectionAmerican Journal of Respiratory and Critical Care Medicine, 2011
- Sterilizing Activity of Second-Line Regimens Containing TMC207 in a Murine Model of TuberculosisPLOS ONE, 2011
- Resuscitation-promoting Factors Reveal an Occult Population of Tubercle Bacilli in SputumAmerican Journal of Respiratory and Critical Care Medicine, 2010
- Diarylquinolines target subunit c of mycobacterial ATP synthaseNature Chemical Biology, 2007
- Synergistic Activity of R207910 Combined with Pyrazinamide against Murine TuberculosisAntimicrobial Agents and Chemotherapy, 2007
- Shortening the treatment of tuberculosisNature Biotechnology, 2005
- A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosisScience, 2005
- Novel Pharmacokinetic-Pharmacodynamic Model forPrediction of Outcomes with an Extended-Release FormulationofCiprofloxacinAntimicrobial Agents and Chemotherapy, 2004
- Dormancy ofMycobacterium tuberculosis and latency of diseaseEuropean Journal of Clinical Microbiology & Infectious Diseases, 1994